Health Updates Webinar #284 “May Gamot Ba Para Di Ma-Infect sa HIV?” Pre-Exposure Prophylaxis (PrEP)

The University of the Philippines,
in partnership with the UP Manila – National Institutes of Health,
and in cooperation with UP Philippine General Hospital and UP College of Medicine,
would like to invite you to attend this webinar!

Registration slots are limited to this HEALTH UPDATES webinar
So sign up NOW:
bit.ly/HealthUpdatesWebinar284

Webinar #284
May 15, 2026 (Friday), 12:00 noon
May Gamot Ba Para Di Ma-Infect sa HIV?
Pre-Exposure Prophylaxis (PrEP)

Presenter:
Dr. Teodora Elvira C. Wi
HIV/AIDS & STI Expert
Team Lead, Sexually Transmitted Infection (STIs)
Department of Global HIV, Hepatitis, and STI Programmes, World Health Organization

———————————————————–

Webinar #284
May 15, 2026 (Friday), 12:00 noon
May Gamot Ba Para Di Ma-Infect sa HIV?
Pre-Exposure Prophylaxis (PrEP)

In the contemporary landscape of global public health, the paradigm of HIV prevention has undergone a transformative shift from purely behavioral interventions to a robust, biomedical framework centered on pharmacologic prophylaxis. As we navigate the complexities of ending the HIV epidemic, Pre-Exposure Prophylaxis, or PrEP, has emerged as a cornerstone of our preventive armamentarium. In this week’s episode, we will have a nuanced discussion on pharmacological profiles of tenofovir-based regimens, specifically focusing on the inhibition of HIV-1 reverse transcriptase as a primary mechanism for preventing viral replication following potential exposure. While the science of PrEP is grounded in rigorous clinical trials and pharmacokinetic data, its success relies heavily on the clinical acumen and empathetic communication of frontline providers. It is no longer sufficient for specialists alone to manage these regimens. Rather, the decentralization of PrEP delivery into primary care, pharmacy-led initiatives, and nursing consultations is essential to mitigate the incidence of seroconversion within vulnerable populations.

We will also discuss the critical clinical eligibility criteria, the importance of baseline and longitudinal renal function monitoring, and the evolving landscape of long-acting injectable formulations versus traditional daily oral dosing. In addition, we will address the systemic challenges of adherence and the sociocultural barriers that often impede equitable access to these life-saving medications.

Our speaker is Dr. Teodora Elvira C. Wi, an HIV/AIDS & STI expert. She is the Team Lead, Sexually Transmitted Infection (STIs) from the Department of Global HIV, Hepatitis, and STI Programmes, World Health Organization HQ. Join us in this intellectual discourse that will help ensure that the promise of a future without new HIV infections becomes a tangible reality.